CY1110195T1 - Διαφορικη διαγνωση νευρολογικων νοσων - Google Patents

Διαφορικη διαγνωση νευρολογικων νοσων

Info

Publication number
CY1110195T1
CY1110195T1 CY20101100635T CY101100635T CY1110195T1 CY 1110195 T1 CY1110195 T1 CY 1110195T1 CY 20101100635 T CY20101100635 T CY 20101100635T CY 101100635 T CY101100635 T CY 101100635T CY 1110195 T1 CY1110195 T1 CY 1110195T1
Authority
CY
Cyprus
Prior art keywords
person suffering
disease
neurological diseases
different diagnosis
dementia
Prior art date
Application number
CY20101100635T
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Frank Hulstaert
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01957875A external-priority patent/EP1295129B1/en
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of CY1110195T1 publication Critical patent/CY1110195T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία μέθοδο για τη διαφορική διάγνωση ενός ατόμου που υποφέρει από τη νόσο του Alzheimer ως προς ένα άτομο που υποφέρει από μία άλλη νευρολογική νόσο. Πιο συγκεκριμένα, η παρούσα εφεύρεση παρέχει μία μέθοδο για τη διαφορική διάγνωση ενός ατόμου που υποφέρει από τη νόσο του Alzheimer ως προς ένα άτομο που υποφέρει από άνοια με σωμάτια του Lewy, ως προς ένα άτομο που υποφέρει από τη νόσο του Parkinson χωρίς άνοια, ως προς ένα άτομο που υποφέρει από ατροφία πολλαπλών συστημάτων και/ή ως προς ένα άτομο που υποφέρει από προϊούσα υπερπυρηνική παράλυση, η οποία μέθοδος χαρακτηρίζεται από το ότι το φωσφο-ταυ χρησιμοποιείται ως νευρολογικός δείκτης.
CY20101100635T 2000-06-30 2010-07-07 Διαφορικη διαγνωση νευρολογικων νοσων CY1110195T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00870151 2000-06-30
US21890700P 2000-07-18 2000-07-18
EP01957875A EP1295129B1 (en) 2000-06-30 2001-06-21 Differential diagnosis of neurological diseases

Publications (1)

Publication Number Publication Date
CY1110195T1 true CY1110195T1 (el) 2015-01-14

Family

ID=26074270

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100635T CY1110195T1 (el) 2000-06-30 2010-07-07 Διαφορικη διαγνωση νευρολογικων νοσων

Country Status (3)

Country Link
US (1) US6670137B2 (el)
CY (1) CY1110195T1 (el)
DE (1) DE60141752D1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090599A2 (en) * 2002-04-25 2003-11-06 Brainsgate Ltd. Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1585430B1 (en) * 2002-11-14 2017-01-11 Brainsgate Ltd. Surgical tools and techniques for stimulation
SG170617A1 (en) * 2003-01-16 2011-05-30 Acadia Pharm Inc Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
JP2010522198A (ja) 2007-03-19 2010-07-01 アカドイア プハルマセウチカルス インコーポレーテッド ５−ｈｔ２ａインバースアゴニスト及びアンタゴニストの抗精神病薬との併用
DK2200610T3 (en) * 2007-09-21 2018-04-23 Acadia Pharm Inc ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2011062782A2 (en) * 2009-11-17 2011-05-26 Servicios Cientificos Neuroinnovation Limitada Innovative blood platelets biomarker for early diagnosis of alzheimer's disease
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
AU2013302540B2 (en) 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2015103594A1 (en) * 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10597363B2 (en) 2015-07-20 2020-03-24 Acadia Pharmaceuticals Inc. Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
TWI644673B (zh) * 2017-07-27 2018-12-21 百朗克股份有限公司 頭孢曲松的用途
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP3762414A4 (en) 2018-03-05 2022-01-05 Janssen Pharmaceutica NV DOSAGES TO DETECT NEURODEGENERENCE
WO2024073794A1 (en) * 2022-10-07 2024-04-11 Actinogen Medical Limited SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
EP0737208B1 (en) 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

Also Published As

Publication number Publication date
US20020019016A1 (en) 2002-02-14
US6670137B2 (en) 2003-12-30
DE60141752D1 (de) 2010-05-20

Similar Documents

Publication Publication Date Title
CY1110195T1 (el) Διαφορικη διαγνωση νευρολογικων νοσων
CO4290416A1 (es) Antagonistas de receptores de taquicinas no-peptidos
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
MXPA02011373A (es) Derivados de triazol.
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ZA200109995B (en) Nematicidal Trifluorobutenes.
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
BR0307998A (pt) Hidroxietilaminas substituìdas
ATE359279T1 (de) Moschus-geruchsstoffe
HUP0303973A2 (hu) Erektogén kompozíciót tartalmazó óvszer
CY1106682T1 (el) Ενωση λακταμης
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
EA199700151A1 (ru) Композиция для чрескожного введения
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
EA200300954A1 (ru) Прегабалин-лактозные конъюгаты
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
EA200100700A1 (ru) Гены и белки и их применение
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
DE60129032D1 (de) Creatinester-pronutrient-verbindungen und formulierungen
HUP0402070A2 (hu) Szigma G-t kódoló gén deletált részeivel rendelkező, nem sporuláló Bacillus subtilis
DK1295129T3 (da) Differentialdiagnose af neurologiske sygdomme
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.